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M. Sheppard*, on behalf of the Pasireotide C2305 Study Group
Context: Biochemical control reduces morbidity and increases life expectancy in patients with
acromegaly. With current medical therapies, including the gold standard octreotide long-acting-
release (LAR), many patients do not achieve biochemical control.
Objective:Ourobjectivewas todemonstrate the superiorityofpasireotideLARoveroctreotideLAR
in medically naive patients with acromegaly.
DesignandSetting:Weconductedaprospective,randomized,double-blindstudyat84sitesin27countries.
Patients:A total of 358 patients withmedically naive acromegaly (GH5g/L or GH nadir1g/L
after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were
enrolled. Patients either had previous pituitary surgery but nomedical treatment or were de novo
with a visible pituitary adenoma on magnetic resonance imaging.
Interventions: Patients receivedpasireotide LAR40mg/28days (n 176) or octreotide LAR20mg/28days
(n182)for12months.Atmonths3and7,titrationtopasireotideLAR60mgoroctreotideLAR30mgwas
permitted, but notmandatory, if GH2.5g/L and/or IGF-1was above the upper limit of normal.
Main Outcome Measure: The main outcome measure was the proportion of patients in each
treatment arm with biochemical control (GH 2.5 g/L and normal IGF-1) at month 12.
Results: Biochemical control was achieved by significantly more pasireotide LAR patients than
octreotide LAR patients (31.3% vs 19.2%; P .007; 35.8% vs 20.9% when including patients with
IGF-1 below the lower normal limit). In pasireotide LAR and octreotide LAR patients, respectively,
38.6% and 23.6% (P .002) achieved normal IGF-1, and 48.3% and 51.6% achieved GH2.5 g/L.
31.0% of pasireotide LAR and 22.2% of octreotide LAR patients who did not achieve biochemical
control did not receive the recommended dose increase. Hyperglycemia-related adverse events
were more common with pasireotide LAR (57.3% vs 21.7%).
Conclusions: Pasireotide LAR demonstrated superior efficacy over octreotide LAR and is a viable
new treatment option for acromegaly. (J Clin Endocrinol Metab 99: 791–799, 2014)
Acromegaly is a rare serious condition characterizedbychronic hypersecretion of GH from a pituitary ad-
enoma. GH induces the synthesis of IGF-1, and elevated
GH and IGF-1 cause metabolic dysfunction and somatic
growth, resulting in significant morbidity and mortality.
Achieving and maintaining control of GH and IGF-1 re-
duces morbidity and restores normal life expectancy for
patientswith acromegaly (1, 2). First-line treatment is usu-
ally transsphenoidal surgery; however, cure rates decrease
with increasing adenoma size, extrasellar extension, and
cavernous sinus invasion (3), and most patients with a
macroadenoma require postsurgical medical treatment to
achieve disease control (4). With current medical thera-
pies,many patients are unable to achieve aGH level below
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2.5 g/L and a normalized IGF-1 level, the composite in-
dicator of biochemical control (5–7).
Pasireotide is a multireceptor-targeted somatostatin
analog with high affinity for 4 of the 5 somatostatin re-
ceptor subtypes (sst), including sst2 and sst5, which are the
most prevalent sst on GH-secreting pituitary adenomas
(8). The efficacy of the twice-daily sc formulation of pa-
sireotide has been demonstrated in patientswith acromeg-
aly (9), and a monthly long-acting-release (LAR) formu-
lation of pasireotide has been developed (10). Here we
present results from a prospective, randomized, double-
blind, multicenter study of pasireotide LAR vs the current
standard of care, octreotide LAR, in medically naive pa-
tients with acromegaly.
Patients and Methods
Patients
Adult patients with active acromegaly confirmed by a 2-hour
5-point mean GH level 5 g/L or lack of suppression of GH
nadir to1g/L after an oral glucose tolerance test and elevated
IGF-1 for age- and sex-matched controls were enrolled. Patients
could have had1 pituitary surgery but not have beenmedically
treated for acromegaly. De novo patients with a pituitary ade-
noma visible on magnetic resonance imaging (MRI) but who
refused pituitary surgery or for whom surgery was contraindi-
cated were also eligible.
Key exclusion criteria were previous treatment with soma-
tostatin analogs, dopamine agonists, or a GH receptor antago-
nist; compression of the optic chiasm causing any visual field
defect; a requirement for surgical intervention for relief of any
sign or symptom associated with tumor compression; pituitary
irradiation within the last 10 years; significant cardiovascular
morbidity and/or liver disease; symptomatic cholelithiasis; and
HbA1c 8%. Significant cardiovascular morbidity was defined
as congestive heart failure (NewYorkHeart Association class III
or IV), unstable angina, sustained ventricular tachycardia, ven-
tricular fibrillation, clinically significant bradycardia, advanced
heart block, or a history of acute myocardial infarction within
the 6 months preceding enrollment.
Study design
This was a prospective, randomized, double-blind, multi-
center, 12-month study.Eligible patientswere randomized1:1 to
pasireotide LAR 40 mg or octreotide LAR 20 mg every 28 days
and were stratified into 2 groups: 1) after pituitary surgery or 2)
de novo. A dose increase to pasireotide LAR 60mg or octreotide
LAR 30 mg was permitted, but not mandatory, at month 3 or 7
based on biochemical response (mean GH 2.5 g/L and/or
IGF-1 above the upper limit of normal [ULN]). Dose decreases
were permitted for tolerability, and the dose could be increased
upon resolution. Because the 2 treatments differ in appearance,
injections were administered on site by an independent, un-
blinded nurse to ensure that patient and investigator were
blinded to treatment.
The study was conducted in accordance with the Declaration
ofHelsinki, andan independent ethics committeeor institutional
reviewboard for each study site approved the study protocol. All
patients provided written informed consent to participate in the
trial (ClinicalTrials.gov NCT00600886).
Study objectives and endpoints
The primary objective was to show superiority of pasireotide
LAR over octreotide LAR in terms of biochemical control (pro-
portion of patients achieving GH 2.5 g/L and normal IGF-1
for age and sex) at month 12. Secondary objectives included
determining proportion of patients achieving GH 2.5 g/L;
proportion of patients achieving normal IGF-1 for age and sex;
meanGH and IGF-1 levels over time; decrease in tumor volume;
change in signs, symptoms, and health-related quality of life
(HRQoL); and safety.
The 5-point mean GH levels (2-hour curve) before drug in-
jection and IGF-1 levels were assessed at baseline and months 3,
6, 9, and 12. Five symptoms of acromegaly (headache, fatigue,
perspiration, paresthesia, and osteoarthralgia) were scored from
0 (no symptom) to 4 (very severe) each month. HRQoL was
assessed using the AcroQoL questionnaire (11), a 22-item in-
strument resulting in scores ranging from 0 (worst HRQoL) to
100 (best HRQoL).
Gadolinium-enhanced pituitaryMRIwas performed at base-
line and at 6 and 12 months and evaluated by a central reader
blinded to treatment.Apituitary tumorvolume changeof20%
from screening was considered significant. Tumor volume was
calculated by hand-drawing around the tumor circumference in
coronal cross-sections, multiplying the area by slice thickness,
and summing the resulting volumes across all slices containing
tumor. For further details, see the Supplemental Appendix (pub-
lished on The Endocrine Society’s Journals Online website at
http://jcem.endojournals.org).
Safety was assessed according to the National Cancer Insti-
tute Common Terminology Criteria (CTC) for Adverse Events
version 3.0 (12) and consisted ofmonitoring and recording of all
adverse events (AEs); regular monitoring of hematology, blood
chemistry, and urinalysis parameters; performance of physical
examinations; and body weight measurements. Blood samples
for laboratory tests, including blood glucose measurements,
were drawn at each visit under fasted conditions before the
morning dose.
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Changes in diabetic category during treatment with pasir-
eotide LAR or octreotide LARwere determined using the Amer-
ican Diabetes Association (13) definitions for diabetic category.
Hormone assays
Serum GH and IGF-1 were measured using validated chemi-
luminescent immunometric assays (Immulite 2000/1000; Diag-
nostic Products Corp [Siemens]; GH International Reference
Preparation World Health Organization National Institute for
Biological Standards and Controls second IS 98/574; IGF-1 In-
ternational Reference Preparation World Health Organization
National Institute for Biological Standards and Controls first
IRR 87/518). The lower limit of detection for GHwas 0.1 g/L,
with intra- and interassay coefficients of variation 6.6%. For
IGF-1, the lower limit of detection was 20 g/L, with intra- and
interassay coefficients of variation 6.7%. IGF-1 values were
compared with age- and sex-standardized normal values. All
samples except for those from China were analyzed by Quest
Diagnostics Nichols Institute Laboratory between March 2008
and March 2010 and then by Quest Diagnostics Clinical Trials
Laboratory from March 2010 onward. Samples from China
were analyzed by KingmedDiagnostics. Subsequent to receiving
a notification from Siemens regarding the Immulite IGF-1 assay,
Quest Diagnostics reviewed all quality control data collected
during this clinical trial and verified that all IGF-1 data are valid.
See the Supplemental Appendix for further details.
Statistical analyses
The primary and secondary efficacy results were based on the
intent-to-treat population. The principle of last observation car-
ried forward (LOCF) was included in the study protocol as an
amendmentwhile the studywasongoing to fully use the response
data in patients who discontinued beforemonth 12 but had been
enrolled in the study for at least 6 months. LOCFwas applied to
the endpoints of biochemical response; ie, if the month-12 mean
GHor IGF-1 value wasmissing, it was imputed by the last avail-
able value betweenmonths 6 and12 (includingmonth6). If there
were no available values between months 6 and 12 (including
months 6 and 12), patients were considered nonresponders.
The null hypothesis was that there would be no difference
between the 2 treatments in the proportion of patients achieving
GH 2.5 g/L and normal IGF-1 at month 12. The alternative
hypothesis was that the response rates would be different. It was
assumed that 75% and 25% of patients would enroll in the
postsurgical and de novo strata, respectively. A sample size of at
least 330 patients was needed to detect a 15% increase in re-
sponse rate from20% in the octreotide LARgroup to 35% in the
pasireotide LAR group, based on a 2-sided Cochran-Mantel-
Haenszel test at the .05 level with 80% power and allowing for
a 9% patient dropout rate.
A Cochran-Mantel-Haenszel test adjusting for randomiza-
tion stratumwas used for the primary and key efficacy analyses.
The analysis of covariance model used for the change in tumor
volumeatmonth12 includes treatment and randomization strat-
ification factor as the fixed effect and baseline tumor volume as
a covariate.
Safety data were analyzed based on the safety population
according to the first treatment received.
Post hoc analyses included the proportion of patients achiev-
ingGH2.5g/L and IGF-1 at or below theULN (patientswith
IGF-1 below the lower normal limit were not considered as re-
sponders in the primary efficacy analyses) and the difference in
the incidence of hyperglycemia-related AEs between the pasir-
eotide LAR and octreotide LAR treatment arms.
Results
In total, 546 patients were screened and 358 patients were
randomized to pasireotide LAR (n  176) or octreotide
LAR (n  182). Two patients randomized to octreotide
LAR received pasireotide LAR in error.
The 2 treatment groups were similar in terms of base-
line demographics and disease characteristics; 58%of pa-
tientswere de novo (Table 1). BaselinemeanGHwas 21.9
and 18.8g/L, baselinemean standardized IGF-1was 3.1
and 3.1 times ULN, and baselinemean tumor volumewas
2421and2259mm3 in thepasireotideLARandoctreotide
LAR groups, respectively.
Overall, 80.1% and 85.7% of pasireotide LAR and
octreotide LAR patients completed 12 months of treat-
Table 1. Patient Demographics and Characteristics
Demographic Variable
Pasireotide LAR,
n  176
Octreotide LAR,
n  182
All Patients,
n  358
Age
Median (range), y 46 (18–80) 45 (19–85) 46 (18–85)
65 y, n (%) 8 (4.5) 15 (8.2) 23 (6.4)
Male, n (%) 85 (48.3) 87 (47.8) 172 (48.0)
Race, n (%)
Caucasian 105 (59.7) 111 (61.0) 216 (60.3)
Black 3 (1.7) 4 (2.2) 7 (2.0)
Asian 39 (22.2) 43 (23.6) 82 (22.9)
Native American 6 (3.4) 5 (2.7) 11 (3.1)
Other 23 (13.1) 19 (10.4) 42 (11.7)
Median time since diagnosis (range), mo 5.6 (0.4–357.5) 6.4 (0.4–377.1) 6.0 (0.4–377.1)
Previous surgery, n (%) 71 (40.3) 80 (44.0) 151 (42.2)
Median time since surgery (range), mo 9.5 (1.6–328.8) 6.2 (1.2–377.1) 7.0 (1.2–377.1)
Previous radiation, n (%) 0 1 (0.5) 1 (0.3)
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ment;median drug exposurewas 336days in both groups.
Themost frequent reasons for discontinuation among pa-
sireotide LAR and octreotide LAR patients, respectively,
were AEs (8.0%and 3.3%) and protocol deviation (4.0%
and 4.4%).
Primary and related endpoints
Significantly more pasireotide LAR patients achieved
biochemical control at month 12 than octreotide LAR pa-
tients (31.3% vs 19.2%; P .007; Figure 1 and Table 2),
with pasireotide LAR patients being 63% more likely to
achievebiochemical control thanoctreotideLARpatients.
The odds ratio (OR) for achieving the primary endpoint,
adjusted for randomization strata, was 1.94 (95% confi-
dence interval [CI], 1.19–3.17) favoring pasireotide LAR.
Biochemical control was achieved by 39.4% of pasir-
eotide LAR patients vs 21.8% of octreotide LAR patients
in the postsurgical stratum (OR, 2.34; 95% CI, 1.14–
4.79) and by 25.7%of pasireotide LARpatients vs 17.3%
of octreotide LAR patients in the de novo stratum (OR,
1.65; 95% CI, 0.85–3.23).
Including 8 pasireotide LAR patients (4 in the postsur-
gical stratum) and 3 octreotide LAR patients (all in the
postsurgical stratum)whohad IGF-1below the lowernor-
mal limit and GH 2.5 g/L, 35.8% (63 of 176) of pa-
sireotide LAR patients and 20.9% (38 of 182) of oc-
treotide LAR patients achieved GH2.5 g/L and IGF-1
levels at or below the ULN (Table 2).
At month 12 in the pasireotide LAR and octreotide
LAR groups, respectively, IGF-1 was normalized in
38.6% and 23.6% of patients (P  .002) and GH 2.5
g/L was achieved by 48.3% and 51.6% of patients (P
.54). Normal IGF-1 was achieved in 50.7% vs 26.9% of
postsurgery and 30.5% vs 21.2% of de novo pasireotide
LAR and octreotide LAR patients. Control of GH was
seen in a similar proportion of postsurgery and de novo
patients with both treatments (Table 2).
For the primary analyses, the last value of GH and
IGF-1 obtained between months 6 and 12 (including
month 6) was carried forward for patients who did not
have GH and IGF-1 values at month 12. Of the 39 pasir-
eotide LAR patients and 31 octreotide LAR patients who
did not haveGHand IGF-1 values atmonth 12, 20 and 21
had their LOCF, and 4 and 3, respectively, were counted
as responders. If these 7 patients were considered nonre-
sponders, biochemical control was achieved by 29.0% of
pasireotide LAR patients vs 17.6% of octreotide LAR pa-
tients (P  .009).
During the 12 months of treatment, 50.6% of pasir-
eotide LAR patients and 67.6% of octreotide LAR pa-
tients received dose up-titration. Of the pasireotide LAR
and octreotide LAR patients who did not achieve GH
2.5 g/L or IGF-1 at or below ULN, 35 of 113 patients
(31.0%) and 32 of 144 patients (22.2%) did not receive a
dose increase. Eleven of the 63 (17.5%) pasireotide LAR
and 11 of the 38 (28.9%) octreotide LAR patients who
achieved GH 2.5 g/L or IGF-1 at or below ULN re-
ceived a dose increase during the 12 months.
Other secondary efficacy endpoints
MeanGHand IGF-1 levels decreased rapidlywithin the
first 3 months and remained low in both treatment arms
(Figure 2). At month 3, 30.1% and 21.4% of pasireotide
LAR and octreotide LAR patients had biochemical
control.
From baseline to month 12, mean tumor volume de-
creased by 40% and 38% in the pasireotide LAR and
octreotide LAR groups, respectively (P .838). A signif-
icant (20%) tumor volume reduction was achieved by
80.8%and77.4%ofpasireotideLARandoctreotideLAR
patients; 1 patient experienced a20% increase in tumor
volume in the octreotide LAR arm (Figure 3). A similar
magnitude of tumor volume reductionwas observed in the
postsurgery and de novo groups.
Both agents were effective at improving the symptoms
of acromegaly and QoL. At baseline, mean AcroQoL
scores were 58.4 (SD, 20.0) in patients receiving pasir-
eotide LAR and 55.6 (SD, 19.8) in patients receiving oc-
treotideLAR.Atmonth12, improvement inQoLwas seen
in both treatment groups. AcroQoL scores had improved
by a mean of 7.0 points (SD, 14.5) in the pasireotide LAR
arm and by a mean of 4.9 points (SD, 15.5) in the oc-
treotide LAR arm. The severity of individual symptoms at
baseline was similar for both treatment arms, with symp-
tom scores between 0.7 and 1.4. Improvements in all 5
Figure 1. Proportion of patients in the overall population, postsurgery
stratum and de novo stratum with GH 2.5 g/L and normal IGF-1
after 12 months of treatment with pasireotide LAR or octreotide LAR.
*, P  .007 pasireotide LAR vs octreotide LAR in the overall
population. The study was not powered to detect treatment
differences in subgroups. The 95% CI of the OR in favor of pasireotide
LAR reached statistical significance at the .05 level for postsurgery
patients (OR, 2.34 [95% CI, 1.14–4.79]) but not de novo patients (OR,
1.65 [95% CI, 0.85–3.23]).
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symptomswere seen bymonth 12. In both treatment arms
(pasireotide LAR and octreotide LAR), the largest im-
provement was in perspiration (mean, 0.6 [SD, 1.14]
and0.8 [SD, 1.20]). Similar improvements were seen in
fatigue (mean,0.4 [SD, 1.18] and0.6 [SD, 0.96]), os-
teoarthralgia (mean, 0.4 [SD, 1.07] and 0.6 [SD,
1.20]), paresthesia (mean,0.4 [SD, 0.90] and0.4 [SD,
1.11]), and headache (mean, 0.3 [SD, 1.17] and 0.4
[SD, 0.94]).
Safety and tolerability
The most common AEs (all CTC grades) with pasir-
eotide LARvs octreotide LAR (Table 3)weremostlymild-
to-moderate diarrhea (39.3% vs 45.0%), cholelithiasis
(25.8% vs 35.6%), headache (18.5% vs 25.6%), and hy-
perglycemia (28.7% vs 8.3%).
When common AE terms were grouped, for example,
all terms relating to elevations in blood glucose or terms
relating to diarrhea, the most common AEs in the pasir-
eotide LAR and octreotide LAR groups were hyperglyce-
mia-related (57.3%[95%CI, 49.7%–64.7%] and21.7%
[95% CI, 15.9%–28.4%]), diarrhea-related (39.3%
[95% CI, 32.1%–46.9%] and 45.0% [95% CI, 37.6%–
52.6%), and gallbladder- and biliary-related (30.9%
[95% CI, 24.2%–38.3%] and 38.9% [95% CI, 31.7%–
46.4%]). Post hoc analysis showed that the difference in
the incidence of hyperglycemia-related AEs between the
pasireotide LAR and octreotide LAR treatment arms was
35.6% (95% CI, 25.5%–44.9%).
Fourteen (8.0%) pasireotide LAR and 6 (3.3%) oc-
treotide LAR patients discontinued because of an AE dur-
ing the 12-month treatment period. The most common
AEs leading to discontinuation in the pasireotide LAR
group were related to elevations in blood glucose (3 be-
cause of diabetes mellitus, 2 because of hyperglycemia,
and 1 because of increased HbA1c). A CTC grade 3 or 4
hyperglycemia-related AE was reported by 9.0% of pa-
sireotide LAR patients and 1.7% of octreotide LAR pa-
tients.At least 1 seriousAEwas experiencedby12.9%and
10.6% of pasireotide LAR and octreotide LAR patients,
and 4.5% and 2.8% of patients experienced 1 or more
serious AEs considered to be study drug-related. Eight pa-
tients (4.5%) discontinued treatment because of a serious
AE, all in the pasireotide LAR arm. One patient in the
octreotide LARgroup died of amyocardial infarction, but
this was not considered study drug-related.
In patients treated with pasireotide LAR or octreotide
LAR, respectively, mean (SD) increases in HbA1c from
baseline to the last available value within 12 months by
baseline diabetic status were: 0.87% (1.32%) and 0.03%
(0.78%) in diabetic patients, 0.64% (0.78%) and 0.11%
(0.35%) in prediabetic patients, and 0.75% (0.58%) and
0.37% (0.46%) in patients with normal glucose tolerance
at baseline.
Table 2. Proportion of Patients at Month 12 With GH 2.5 g/L and Normal IGF-1, GH 2.5 g/L, and Normal
IGF-1, by Stratum and Treatmenta
Pasireotide LAR,b %
(n/N) (95% CI)
Octreotide LAR,b %
(n/N) (95% CI)
Between Treatments
OR (95% CI)
P
Value
n 176 182
GH 2.5 g/L and normal IGF-1 at
month 12 (LOCF)
Overall 31.3 (55/176) (24.5–38.7) 19.2 (35/182) (13.8–25.7) 1.94 (1.19–3.17) .007
After surgery 39.4 (28/71) (28.0–51.7) 21.8 (17/78) (13.2–32.6) 2.34 (1.14–4.79)
De novo 25.7 (27/105) (17.7–35.2) 17.3 (18/104) (10.6–26.0) 1.65 (0.85–3.23)
GH 2.5 g/L at month 12 (LOCF)
Overall 48.3 (85/176) (40.7–55.9) 51.6 (94/182) (44.1–59.1) 0.88 (0.58–1.33) .54
After surgery 52.1 (37/71) (39.9–64.1) 51.3 (40/78) (39.7–62.8) 1.03 (0.54–1.97)
De novo 45.7 (48/105) (36.0–55.7) 51.9 (54/104) (41.9–61.8) 0.78 (0.45–1.34)
Normal IGF-1 at month 12 (LOCF)
Overall 38.6 (68/176) (31.4–46.3) 23.6 (43/182) (17.7–30.5) 2.09 (1.32–3.31) .002
After surgery 50.7 (36/71) (38.6–62.8) 26.9 (21/78) (17.5–38.2) 2.79 (1.41–5.53)
De novo 30.5 (32/105) (21.9–40.2) 21.2 (22/104) (13.8–30.3) 1.63 (0.87–3.06)
GH 2.5 g/L and IGF-1 below the
upper normal limit at month 12 (LOCF)
Overall 35.8 (63/176) 20.9 (38/182)
After surgery 45.1 (32/71) 25.6 (20/78)
De novo 29.5 (31/105) 17.3 (18/104)
a After surgery indicates patients who were medical treatment-naive after surgery; de novo indicates treatment-naïve. P values are based on a 2-
sided Cochran-Mantel-Haenszel test, adjusting for randomization stratification factor.
b Dose up-titration was recommended but performed at the discretion of the investigator.
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The mean time to the first report of a glucose abnor-
mality was 84 days for pasireotide LAR and 196 days for
octreotide LAR. The mean time to first antidiabetic med-
ication was 123 and 212 days in the pasireotide LAR and
octreotide LAR arms, respectively. Antidiabetic medica-
tion was received by 44.4% and 26.1% of pasireotide
LAR and octreotide LAR patients. Metformin and sulfo-
nylureas were most commonly used.
Discussion
This is the largest randomized, active-comparator–con-
trolled trial in patients with acromegaly. It is also one of
the few studies to enroll patients naive to medical therapy
and to strictly report biochemical control using the criteria
of both GH2.5 g/L and normal IGF-1 for age and sex.
Pasireotide LAR provided strong suppression of IGF-1,
and patientswere 63%more likely to achieve biochemical
control with pasireotide LAR. The proportion of patients
withbiochemical controlwashigherwithpasireotideLAR
than with octreotide LAR in both the de novo and post-
surgical strata.
In 2010, the Acromegaly Consensus Group indicated
that a random GH level of 1.0 g/L, using an ultrasen-
sitive GH assay, and normal IGF-1 for age and sex indi-
cates controlled disease (14). Earlier studies measuring
GH by RIA suggested that a random GH level of 2.5
g/L and normal IGF-1 for age and sex is associated with
normal life expectancy (2). The protocol for the current
study was finalized in 2007. At that time, acromegaly
management guidelines recommendeda targetGHlevel of
2.5 g/L (15), so the target GH level in this study was 2.5
g/L. Nonetheless, current guidelines should be adhered
to in clinical practice, with an on-treatment target GH
level of 1.0 g/L.
With respect to hormone secretion, it is of interest that
pasireotide LAR was significantly more effective than oc-
treotide LAR at inhibiting IGF-1 but that the 2 drugs had
a similar effect on GH inhibition. This superior effect on
IGF-1 by pasireotide is important, because most of the
effects of GH are mediated by IGF-1. It has been postu-
lated that somatostatin analogs may act on both the pi-
tuitary and on peripheral target tissues of GH to reduce
GH-induced IGF-1 production (16) and that the nonpi-
tuitary action of somatostatin analogs on the GH/IGF-1
axismay be due to antagonismof the
action of GH on hepatic IGF-1 as
well as insulin suppression (17). The
fact that pasireotide was more effec-
tive than octreotide at suppressing
IGF-1 in the current study may be
due to the higher affinity and func-
tional activity of pasireotide at he-
patic sst1, sst3, or sst5 receptors.
An unexpectedly large number of
de novo patients were enrolled in the
trial; 58% of patients were de novo
and 42%were postsurgical. TheGH
Figure 2. Mean  SE GH levels (A) and standardized IGF-1 levels (B)
over time by treatment group. The numbers at the bottom of each
graph are the numbers of patients in the pasireotide LAR/octreotide
LAR treatment groups. Standardized IGF-1 is the IGF-1 value divided by
the ULN range.
Figure 3. Percent change in tumor volume from baseline to month 12 in patients with baseline
and month-12 MRI assessments.
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and IGF-1 inclusion criteria for the study were GH 1
g/Lafter anOGTTora5-pointmean serumGH5g/L
and IGF-1 above the ULN for age- and sex-matched con-
trols. The serumGHentry criterion is considered high and
may have caused a more difficult-to-treat patient popula-
tion to be enrolled. For example, GH and IGF-1 levels are
often higher in patients with newly diagnosed acromegaly
than in patients with active acromegaly who have under-
gone previous surgery (18).
Nonetheless, the octreotide LAR response rate for bio-
chemical control in the present study (19.2%) is consistent
with recent prospective studies of octreotide LAR in pa-
tients with de novo acromegaly, where results from the
intention-to-treat populationwere reported after 1 year of
treatment. In 2 recent studies of octreotideLAR inpatients
with de novo acromegaly, biochemical control was
achieved in 17% and 27% of the intent-to-treat popula-
tion after 48weeks treatmentwith octreotideLARas first-
line therapy (5, 7). Indeed, it was on the basis of these
results (5, 7) that the current study was designed with an
expected response rateof20%foroctreotideLAR.Similar
results have been seen in medically naive patients with
acromegaly treated with lanreotide Autogel in a recent
international prospective clinical trial (6). Early open-la-
bel studies of octreotide LAR as second-line therapy re-
ported GH and IGF-1 response rates of 55% to 70% and
64%to66%, respectively (19–21).However, a composite
endpoint of GH and IGF-1 control was not reported in
these studies, inwhich the rate of controlwas evaluated by
summing the number of patients with either GH 2.5
g/L or normal IGF-1, and patients were preselected for
responsiveness to octreotide.
Studies with conventional somatostatin analogs have
shown that higher response rates canbe achievedwhen the
somatostatin analog dose is increased and dose titration is
rigorously performed (22). The study protocol permitted
dose up-titration at month 3 or 7 if patients were not
biochemically controlled. However, the decision to up-
titrate was left to the discretion of the investigator; 31.0%
of pasireotide LAR and 22.2%of octreotide LARpatients
who did not achieve biochemical control did not receive
the recommended dose increase. Although it is of some
concern that these patients were not dose up-titrated, the
reasons for not increasing the dose were not collected. As
such, the response rates for both pasireotide LAR and
octreotide LARmight have been higher had these patients
received the recommended dose increase.
The doses of pasireotide LAR used in this study were
selected based on pharmacokinetic data from earlier stud-
ies of pasireotide in patients with acromegaly (9, 23, 24).
A study in 35 patients with acromegaly showed that the
trough concentrations of pasireotide at steady state (28
days after the third injection) were 3.8  2.1, 6.4  3.1,
and 13.7  9.6 ng/mL after 3 monthly injections of pa-
sireotide LAR 20, 40, and 60 mg, respectively (23). The
trough concentrations after the 40- and 60-mg doses, but
not the 20-mg dose, were above the median value of ef-
fective concentration required for GH normalization in
responders topasireotide sc treatment, basedondata from
a3-month studyofpasireotide200,400, and600g scbid
Table 3. Adverse Events Regardless of Study-Drug Relationship Reported in 10% of Patients in Either Treatment
Group
Pasireotide LAR, n  178a Octreotide LAR, n  180a
All Grades,
n (%)
Grade 3/4,
n (%)
All Grades,
n (%)
Grade 3/4,
n (%)
Diarrhea 70 (39.3) 1 (0.6) 81 (45.0) 4 (2.2)
Hyperglycemia 51 (28.7) 6 (3.4) 15 (8.3) 1 (0.6)
Cholelithiasis 46 (25.8) 1 (0.6) 64 (35.6) 2 (1.1)
Diabetes mellitus 34 (19.1) 9 (5.1) 7 (3.9) 0
Headache 33 (18.5) 2 (1.1) 46 (25.6) 5 (2.8)
Abdominal pain 32 (18.0) 1 (0.6) 40 (22.2) 0
Alopecia 32 (18.0) 0 35 (19.4) 0
Nasopharyngitis 28 (15.7) 0 28 (15.6) 0
Nausea 24 (13.5) 1 (0.6) 39 (21.7) 0
Increased blood creatine
phosphokinase
23 (12.9) 3 (1.7) 21 (11.7) 4 (2.2)
Abdominal distension 21 (11.8) 1 (0.6) 21 (11.7) 1 (0.6)
Arthralgia 17 (9.6) 1 (0.6) 22 (12.2) 1 (0.6)
Fatigue 17 (9.6) 1 (0.6) 18 (10.0) 0
Dizziness 17 (9.6) 0 19 (10.6) 0
Back pain 14 (7.9) 0 20 (11.1) 2 (1.1)
a Two patients randomized to the octreotide LAR treatment arm received pasireotide LAR in error. These 2 patients are included in the pasireotide
LAR treatment arm for the purposes of the safety analysis.
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(twice per day) in patients with acromegaly (24, 25).
Therefore, pasireotide LAR40mgwas chosen as the start-
ing dose for the current study. The starting dose of oc-
treotide LARwas based on the recommended posology in
the Sandostatin LAR label.
The most common AEs in both groups were gastroin-
testinal, as expected with somatostatin analogs, and oc-
curred early in the course of treatment. Hyperglycemia-
related AEs were more frequently reported in the
pasireotide LAR group. This suggests that in patients who
develop hyperglycemia that cannot be controlled, the ben-
efits of pasireotide LAR with respect to biochemical con-
trol may be offset. However, no specific guidance on how
tomanage hyperglycemiawas given in the study protocol.
At the time of study initiation, the mechanism behind the
increase in glucose levels during pasireotide LAR treat-
ment was unknown and it was recommended in the study
protocol that current American and European diabetes
mellitus guidelines should be followed. Subsequently, 2
studies in healthy volunteers showed that pasireotide in-
hibited insulin secretion and incretin response, with min-
imal inhibition of glucagon secretion and no impact on
insulin sensitivity, and that dipeptidyl peptidase-4 inhib-
itors andglucagon-likepeptide-1agonistswere effectiveat
ameliorating pasireotide-induced hyperglycemia (26, 27).
Blood glucose levels should be closely monitored in pa-
tients treated with pasireotide, and treatment should be
promptly initiated if blood glucose levels increase accord-
ing to established guidelines until themost effectiveway to
prevent or control increases in blood glucose has been
confirmed in further studies.
This study confirms that pasireotide LAR achieves
greater suppression of IGF-1 than octreotide LAR and is
significantly superior to octreotide LAR at providing bio-
chemical control. The safety profile of pasireotide LAR
was as expected for a somatostatin analog, except for the
degree of hyperglycemia. In conclusion, pasireotide LAR
demonstrated superior efficacyoveroctreotideLARand is
a viable new treatment option for acromegaly.
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